Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25050341 | 1.00 | NPC1 (0.38) | NPC1RAB9ATBXAS1KMT2ACYP1A2 | |
| SCHEMBL25049870 | 1.00 | NPC1 (0.38) | NPC1RAB9ATBXAS1KMT2ACYP1A2 | |
| SCHEMBL31740471 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL28846272 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL1960318 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL4186060 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL2916184 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL10618776 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL6518862 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A | |
| SCHEMBL2913100 | 0.75 | DAGLA (0.48) | TBXAS1KMT2APLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | NPC1 2111/4885RAB9A 3583/4885TBXAS1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.